NDAORALTABLET
Approved
Jul 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Kemadrin (procyclidine hydrochloride) is an oral anticholinergic agent approved in 1955 for managing extrapyramidal side effects associated with antipsychotic medications. It functions by blocking acetylcholine receptors in the central nervous system to reduce involuntary movements and tremor. The drug is indicated for patients experiencing drug-induced parkinsonism and related movement disorders.
LOE Approaching
Legacy product approaching loss of exclusivity with minimal commercial infrastructure; team size likely small and focused on maintenance rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Kemadrin offers limited growth potential given its LOE-approaching lifecycle and zero linked job openings; roles are primarily defensive, focused on generic containment and regulatory compliance. Career advancement will be constrained compared to growth-stage products.
Brand ManagerField Sales Representative
Worked on KEMADRIN at Monarch Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.